Therapies with a MAPK family MEK1/2 inhibitor (trametinib), cell cycle family cyclin D1/CDK4 and CDK6 inhibitor, (Ribociclib), and an mTOR inhibitor (everolimus) had no effect on tumor progression and the patient passed away 16 months from initial diagnosis. Here, MTOR is linked to neoplasm.